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Introduction
Migraine in children affects the quality of life due to its disabling qualification. It 
leads to absence from school; therefore, it has negative impact on the child’s school 
achievement and social and family life. The prevalence of childhood migraine 
ranges from 2.7 to 10% (1). Approximately 3-5% of school-aged children are 
afflicted by this entity. This ratio reaches 20% through adolescence. At lower age 
the predominance is towards boys eventually shifting in the direction of female 
gender through adolescence which remains through adulthood (2, 3).
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Abstract
Objective 
Headache is a common disabling neurological disorder and migraine 
comprises more than half the causes of recurrent headaches in children. 
Despite extended prevalence of this type of headache there is lack of 
evidence about best drug treatment for migraine. So we aimed to compare 
the therapeutic effects of these drugs on childhood migraine. 
Materials & Methods 
In the current study, a randomized clinical trial consisting of 78 patients 
according to 2004 International Headache Association criteria were 
randomly assigned to two groups that matched by age and sex. One 
of these two groups was treated with Topiramate, while the other was 
given Propranolol. After one and four months, the efficiency of these 
treatments was measured in terms of frequency, severity and duration of 
migraine attacks. 
Results
Results obtained from the data collected showed that of these 78 studied 
patients, 38 patients received Topiramate treatment (group A) and the rest 
(40 patients; group B) was treated with Propranolol. The average age of 
group A was 8.5± 2.9 years and that of group B was 8.3 ± 2.8 years. No 
significant difference was observed between these two groups in terms of 
reduction in frequency, severity and duration of migraine attacks. 
Conclusion
Results showed that both treatments had the same efficiency in healing 
migraine headaches and there was no significant difference between their 
treating results. However, further studies are needed to examine medical 
effects of these two medicines. 
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the 2004 international headache society criteria (12), 
were enrolled into our study. The inclusion criteria was 
one of the following:
1. More than three headaches per month
2. Severe disabling or intolerable headache
For all the patients who met the inclusion criteria, we 
recorded the duration, severity and frequency, for a period 
of one month before receiving the drug prophylaxis. 
They were evaluated in our follow up clinic after one 
month (first visit) and four month (second visit) for the 
same above mentioned headache parameters. Then these 
results were compared to pre-treatment state. Patients 
with a past trial of migraine prophylactic agent, persistent 
increasing headache, change of behavior, school 
performance, increased pain with the valsalva maneuver, 
abnormal physical examination (such as papilledema), 
persistent focal neurological signs, neuroimaging studies 
indicating a focal neurological lesion, contraindication 
for Topiramate or Propranolol (such as asthma), were 
excluded from the study. For the patients who entered the 
study, complete physical and neurological examination, 
baseline laboratory screening test and neuroimaging 
studies if necessary were performed. Consequently, the 
patients randomly were divided into two groups that 
matched by age and sex. Group A (n=44) received 50-
100 mg daily Topiramate and group B (n=42) received 
20-80 mg daily Propranolol, with at least 4 months 
follow up.  
The severity of headache was ranked as follows (3).
1. It does not affect daily activities
2.  It roughly disturbs daily activities
3.  It hampers daily activities. 
Then, the data newly obtained from the groups was 
compared with each other and with their prior-to-
treatment data.
Descriptive statistics (including mean, median, range, 
and standard deviation, frequency and frequency 
percentage) were determined using statistical software 
SPSS 18th version. For comparison of quantitative 
means, independent sample t-test was used after 
confirmation of normal distribution of data by one-
sample Kolmogorov-Smirnov, repeated measurement, 
ANOVA, Friedman tests. The chi-square test was used 
for qualitative comparisons. In all tests, the significance 
level was considered as two tails and p <0. 05.
One of the first steps of management of this disabling 
condition is lifestyle modifications including avoiding 
certain foods and habits that may have a trigger effect, 
medication and prevention. Some patients do not 
respond to these changes and need further efforts for 
appropriate headache control. Higher than three to 
four monthly headaches may be the indication to start 
prophylactic treatment in a patient (4). 
In 1966, Rabkin et al. accidentally recognized the 
impact of Propranolol for prophylaxis of migraine on 
patients who were under this medication for angina 
pectoris treatment. Anti-convulsant drugs have also 
been experimented for migraine prophylaxis since 
1970 with carbamazepine as the first drug of this group 
(5).
Preventive measures which may be pharmacological or 
nonpharmacological are approved by some studies in 
case the number of headache episodes are more than 
three to four in a month or if the attacks are expressively 
as measured in the Pediatric Migraine Disability 
Assessment Scale (PedMIDAS) (6,7). PedMIDAS is 
a validated six-item questionnaire based on the adult 
MIDAS tool (8). It has been changed according to 
childhood lifestyle. The questions are concerned with 
the influence of headache on school performance such 
as whole day and partial day absences from school, 
50% or less school functioning, ability to perform 
homework and chores and on social abilities such as 
sports (9,10). 
For the prevention of migraine in children no drugs have 
been approved by the Food and Drug Administration 
(FDA) at the present time (11). Topiramate, an 
antiepileptic drug approved by FDA, has been used 
for the preventive treatment of migraine in adults and 
also the treatment of partial-onset seizures and primary 
generalized tonic-clonic seizures as additional therapy 
in children. The objective of this study was to study 
the prophylactic efficiency of Topiramate in childhood 
migraine and to compare it with Propranolol.
Materials & Methods
This study was a randomized controlled trial that 
compared the efficacy of Topiramate with Propranolol in 
the prophylaxis of pediatric common migraine. Children 
aged 3-15 years with common migraine, as defined by 
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and second visits (P>0.05) between the groups during 
treatment.
In addition, the results revealed that from the statistical 
aspect, there was no significant difference between the 
average frequencies of attacks obtained for both groups 
in three visits (one held before medicine prescription and 
two sessions at the end of the one and four months after 
medicine prescription) (P>0.05).
The data shown in Table 3 presents comparison of 
headache severity obtained in different visits of patients 
suffering from migraine headache receiving treatment 
with Propranolol and Topiramate. As observed, the 
severity of headache attacks of both groups was reduced 
in visits held after medicine prescription. So, a significant 
difference was found between the severity of headache 
attacks in both groups in various visits (P=0.001); 
demonstrating that both medicines were successful in 
reducing the patients headache severity of people under 
examination.
However, the results showed no significant difference 
statistically between the two groups regarding the 
severity of the attacks in all visits (a visit prior to 
medicine prescription and two visits at the end of one 
and four months from medicine prescription) (P>0.05). 
The data shown in Table 4 compares the average 
duration of each headache attack which was reported 
in the different visits. Again, a decrease was observed 
in the average headache duration in both groups after 
the treatments were started. Additionally, a significant 
difference was statistically revealed between the average 
headache duration of various visits in each group 
(P=0.001); in other words, both treatments succeeded in 
decreasing the average duration of migraine headache in 
both groups. 
Discussion 
The result obtained from the present study shows that 
both Topiramate and Propranolol are effective in the 
prevention of children migraine and in reducing the 
number, severity and duration of migraine attacks as 
well. However, an effective Topiramate dosage needed 
to prevent migraine is less than that required to prevent 
epilepsy. A 50-100 mg dosage of Topiramate is of great 
effect in migraine prevention. However, 14% of the 
Topiramate-treated group stopped receiving medicine 
As a research study this proposal acquired the Ethical 
Committee certificate of Pediatric Neurology Research 
Center.
Results 
Fourth-four patients of group A out of totally 86 
patients received Topiramate and the remainder 42 
patients of group B were treated with Propranolol. Six 
patients of group A were discarded; three patients due 
to drug allergy, one because of a disorder generated in 
educational performance and the other two patients as 
the result of lack of compliance. Of group B also two 
patients stopped being under examination; one without 
informing the researcher and the other due to suffering 
from asthma. 
In the Topiramate group, the average age of the patients 
was 8.5±2.9 years and that of the other group was 
8.3±2.8 years. No significant difference was observed 
between these groups in terms of average age of patients 
(P=0.718). 
Regarding the aspect of age groups, we did not find any 
significant difference between the two groups (P=0.890) 
(Table1). Nineteen patients (50%) of the Topiramate 
group and 21 participants (52.5%) of the Propranolol 
group were boys. Therefore, no significant difference 
was statistically found between the two groups regarding 
gender (P=1.0).
The data shown in Table 2 indicate comparison of average 
headache frequencies obtained in various visits of under 
examination patients suffering from migraine headache 
who were treated with Propranolol and Topiramate. As 
observed, the average frequency of headache attacks 
obtained from both groups in the visits during treatment 
shows a decrease in a way that a significant difference 
was generated between average frequencies of headache 
attacks obtained in various visits in both groups 
(P=0.001). These results highlight the fact that both 
medicines reduce the average frequency of headache 
attacks of patients under examination.
Both groups showed a significant difference between the 
average frequency of headache attacks in pre-treatment 
visits (P=0.001) and those of first visits (P=0.001) and 
second visits (P=0.001) carried out during treatment. 
However, no significant difference was seen between 
the average frequencies of headache attacks in the first 
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due to its side effects, while within the Propranolol-
treated group only one participant failed to carry on 
treatment as the result of asthma.
Through a decrease generated in the severity level and 
duration of headache attacks, the number of days the 
students were absent from school was reduced and an 
improvement of quality of life was achieved. According 
to a random double blind study conducted by Lipton et 
al., 44 children were randomly assigned to two groups, 
each receiving Topiramate and placebo for a period of 12 
weeks. Preliminary results were evaluated as a reduction 
in both attack frequency and duration and secondary 
results were examined as performance disability due to 
severe headache and reduction in number of sedatives 
received. The number of migraine attacks decreased 
in both groups some weeks after treatment. 95.2% of 
those treated with Topiramate revealed a more than 50% 
reduction in headache frequency compared to that of the 
placebo-treated group (51.4%). The amount of disability 
caused because of migraine dramatically decreased. 
The uppermost side effects of Topiramate in this 
study were reported as loss of weight (23.8%), loss of 
appetite (23.8%), reduction of concentration (19%) and 
stomachache (14.3%) (13). Our study; however, did not 
find any significant difference between the two groups 
separately receiving Topiramate and Propranolol, the 
averages of headache numbers and duration showed a 
decrease in both groups.
Another random double blind research by Winner et al. 
was carried out on 131 children aged 6 to 15-year-old, 
receiving a 1:2 ratio of Topiramate and placebo. In the 
first stage, a reduction in the number of headache days 
was reported within the first month of follow up. The 
second stage which was the end of the fourth week was 
accompanied by a decrease in the duration of headache. 
The monthly average reduction of headache days in the 
Topiramate-treated group was more than 75% when 
compared to that of the control group (14%) (14). The 
current study also found an average reduction of two 
days in the headache-attack period of the group receiving 
Topiramate in the first visit and an average reduction 
of four days in the second visit, while the Propranolol-
treated group revealed a three-day reduction in the first 
visit and a two-day decrease in the second visit.
According to Silbersteins study conducted to investigate 
the impact of Topiramate on migraine prevention, 30% 
of the participants revealed more than 60% reductions in 
the number of attacks occurred. Besides, the headache 
frequency decreased by 40-60 percent in 30% of the 
patients (15). The present study showed  more than 60 
% reduction in headache frequency in 55% of  patients 
and  40-60 percent reduction in 24% of participants in 
the first follow up visit (after one month) of topiramte 
treatment.
According to Goods et al, Topiramate was effective in 
reducing the frequency and severity level of headaches 
and vertigo (P=0.01) (16). Other articles argued that 
Topiramate could be of great effect to cure migraine, 
although further studies are needed to be conducted 
(11). In agreement with the above mentioned argument, 
our study found that Topiramate could be applied to 
control headache attacks; however, it did not find any 
significant difference between the impact of Topiramate 
and Propranolol in this regard. 
In an investigation to compare Topiramate and 
Propranolol, Ashtari et al. suggested that low Topiramate 
dosage was not only effective in migraine therapy, 
but it also generated few side effects and Topiramate 
effectiveness was greater compared to that of Propranolol 
[9]; however, no significant difference was observed 
between the treatment ability of these medications here. 
As previously discussed, results obtained by the current 
article recommend application of both medicines and 
confirm their curing results, but do not prefer one over 
the other.
Suggestions 
• Topiramate and Propranolol may be applied to cure 
migraine headache; however, decision on which one to 
use depends on the patient’s situation.
• A comprehensive research needs to be designed and 
conducted to study Topiramate treatment for a longer 
period of time. 
Acknowledgment
This work was supported by grants from the Pediatric 
Neurology Research Center of Shahid Beheshti University 
of Medical Sciences. The authors wish to thank Clinical 
Research Development Center, Mofid Children’s Hospital 
for helping us with the statistical analysis. 
Prophylaxis of Childhood Migraine: Topiramate versus Propranolol
13Iran J Child Neurology Vol 7 No 1 2013 Winter





0-5 6 (15%) 7 (18.4%) 13 (16.7%) 
6-8 17 (42.5%) 13 (34.2%) 30 (38.5%) 
9-11 10 (25%) 10 (26.3%) 20 (25.6%) 
12-15 7 (17.5%) 8 (21.1%) 15 (92.2%) 
Total 40 (100%) 38 (100%) 78 (100%) 
Table 2. Comparison of the Average Number of Headaches (in a Week/Month)




(range) average± SD (range) average± SD
Pre treatment (2-20)  8.1±6.9 (3-20) 7.0±4.3 0.721
First visit (0-16) 3.1±3.6 (0-16) 3.1±3.9 0.939
Second visit (0-16) 1.8±3.1 (0-16)  2.3±4.0 0.643
P-value <0.001 <0.001 --




1 2 3 1 2 3
Pre treatment 16 16 8 15 11 12 0.426
First visit 28 11 1 24 10 4 0.349
Second visit 34 5 1 32 4 2 0.797
P-value <0.001 <0.001 -
Table 4. Comparison of the Average Duration of Headache Attacks




(range) average± SD (range) average± SD
Pre treatment (1-18) 5.5±4.0 (2-15)  5.4±3.3 0.536
First visit (0-15) 2.9±3.6 (0-15) 2.8±3.1 0.835
Second visit (0-15) 2.6±3.9 (0-15) 2.2±3.0 0.827
P-value <0.001 <0.001 --
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